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Abstract
Background: Insulin gene (INS) mutations have recently been described as a common cause of permanent
neonatal diabetes (PNDM) and a rare cause of diabetes diagnosed in childhood or adulthood.
Methods: INS was sequenced in 116 maturity-onset diabetes of the young (MODYX) patients (n = 48 Danish and
n = 68 Czech), 83 patients with gestational diabetes mellitus (GDM), 34 type 1 diabetic patients screened negative
for glutamic acid decarboxylase (GAD), and 96 glucose tolerant individuals. The control group was randomly
selected from the population-based sampled Inter99 study.
Results: One novel heterozygous mutation c.17G>A, R6H, was identified in the pre-proinsulin gene (INS)i na
Danish MODYX family. The proband was diagnosed at 20 years of age with mild diabetes and treated with diet
and oral hypoglycaemic agent. Two other family members who carried the INS R6H were diagnosed with diabetes
when 51 years old and with GDM when 27 years old, respectively. A fourth mutation carrier had normal glucose
tolerance when 20 years old. Two carriers of INS R6H were also examined twice with an oral glucose tolerance test
(OGTT) with 5 years interval. They both had a ~30% reduction in beta-cell function measured as insulinogenic
index. In a Czech MODYX family a previously described R46Q mutation was found. The proband was diagnosed at
13 years of age and had been treated with insulin since onset of diabetes. Her mother and grandmother were
diagnosed at 14 and 35 years of age, respectively, and were treated with oral hypoglycaemic agents and/or insulin.
Conclusion: Mutations in INS can be a rare cause of MODY and we conclude that screening for mutations in INS
should be recommended in MODYX patients.
Background
Insulin gene (INS) mutations have recently been
described as a common cause of permanent neonatal
diabetes (PNDM) and a rare cause of diabetes diagnosed
in childhood or adulthood [1-4]. Heterozygous muta-
tions in INS account for 15 - 20% of cases of PNDM
[4,5]. Gene discovery can lead to recognition of novel
phenotypes [6] and recognition of novel clinical sub-
groups. For example, MODY was initially clinically
defined as autosomal dominantly inherited, non insulin
dependent, early-onset diabetes, but now there are at
least eight distinct genetic subgroups of MODY, most of
which have a discrete phenotype and specialized treat-
ment needs [6]. An R46Q INS mutation was recently
described in a Norwegian study of 62 probands fulfilling
conventional MODY criteria. In addition, they examined
223 patients from the population-based Norwegian
Childhood Diabetes Registry and found an R55C INS
mutation. One hundred blood donors were screened
negative for these mutations [7]. The Italian study group
on early onset diabetes has detected two INS mutations
( A 2 3 Sa n dG 2 3 S )i nc h i l d r e nn e g a t i v ef o r5t y p e1d i a -
betes (T1D) autoantibodies [1]. In addition, an R6C
mutation was identified in an English MODY family and
a L68M mutation was described in a family of Turkish
origin with young-onset type 2 diabetes [3]. * Correspondence: tweb@hagedorn.dk
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252 patients diagnosed clinically with T1D between 6
months and 17 years of age identified 2 de novo hetero-
zygous mutations G32S and R89C among the 25 (8%)
antibody-negative patients [8]. To our knowledge, no
studies have screened women with gestational diabetes
mellitus (GDM) for INS mutation. GDM was defined as
an abnormal glucose tolerance diagnosed for the first
time in pregnancy.
We aimed to evaluate the prevalence and the disease-
associated phenotype of INS mutations among diabetic
patients diagnosed with MODY, anti-body negative T1D
or GDM.
Methods
INS was sequenced in 116 unrelated MODYX probands:
48 Danish, age at diagnosis (mean ± SD) 24 ± 19 years,
BMI 24.8 ± 5.5 kg/m
2, and 68 Czech, age at diagnosis
18 ± 8 years, BMI 22.6 ± 5.0 kg/m
2,8 3D a n i s hd i a b e t i c
patients previously diagnosed with GDM, age at examina-
tion 40 ± 7 years, BMI at examination 28.1 ± 6.5 kg/m
2,
34 GAD autoantibody-negative T1D patients, age at
diagnosis 20 ± 16 years and 96 glucose tolerant control
individuals, age at examination 46 ± 7 years, BMI 26.4 ±
4.4 kg/m
2. All MODYX probands were from families
fulfilling the conventional criteria of MODY [5] defined
by: diabetes diagnosed before 25 years of age in at least
one of the family members. No treatment with insulin
and/or measurable C-peptide at least one year after
diagnosis. Autosomal dominant inherited diabetes with
known diabetes in at least two consecutive generations.
All MODY probands were screened negative for muta-
tions in the MODY genes HNF4A, GCK and HNF1A.
Women with GDM and all GAD autoantibody-negative
T1D patients had a positive family history of diabetes
including a diabetic parents and or child with diabetes.
The control group was randomly selected from the
population-based study Inter99 [9]. Additional family
members of the probands with an INS mutation were
examined and screened for the family-specific INS
mutation. The participants and examined family mem-
bers gave their informed written consent, and the study
protocols were approved by the ethical committees. The
genomic sequence of INS was analysed in two segments
covering the two exons, exon-intron boundaries and
UTRs. Sequencing analyses were performed as described
[4]. Analyses of the INS sequence revealed four low-
frequency (minor allele frequency = 0.05) and three
frequent (minor allele frequency>0.05) variants (Table 1).
Results and Discussion
One novel mutation c.17G>A, R6H, was identified in
INS in a Danish MODYX family (Figure 1A). The muta-
tion is located in the signal peptide of proinsulin and
was not present in 96 control individuals. The proband,
M132-1, had been diagnosed at 20 years of age with
mild diabetes treated with diet and oral hypoglycaemic
agent (OHA). His 20-years-old son, M132-2, carried the
mutation but had normal glucose tolerance. The brother
of the proband, M132-4, carried the mutation and
had been diagnosed with diabetes at 51 years of age.
A daughter, M132-5, of the brother carried the mutation
and had been diagnosed with IGT at the age of 26 and
with GDM at the age of 27 years. Two carriers of INS
R6H, M132-2 and M132-4, were also examined with an
OGTT at age 15 years and 46 years, respectively. Inter-
estingly, they both had a ~30% reduction in beta-cell
function over a period of 5 years measured as insulino-
genic index calculated from OGTT data (s-insulin 30
min (pmol/l) - s-insulin 0 min (pmol/l)/p-glucose 30
min (mmol/l). Insulinogenic index of M132-2 declined
from 50 to 33 and for M132-4 from 19 to 13. BMI for
M132-2 increased from 19.7 to 24.8 kg/m
2;f o rM 1 3 2 - 4
BMI was unchanged, 24.2 kg/m
2, over the 5-year period.
Table 1 INS gene variants identified in MODY (n = 116), T1DM (n = 34), GDM (n = 83) and controls (n = 96)
MAF (%)
rs number SNP Position on chr. 11 Part of gene MODY
(n = 116)
T1D ab
-
(n = 34)
GDM
(n = 83)
Controls
(n = 92)
Novel c.-218A>C 2.138.995 5’UTR 0.4 0 0 0
rs689 c.-23A>T 2.138.800 Intron 27 10 33 28
rs5505 c.-9C>T 2.138.786 5’UTR 0.9 0 0.6 0
A
Novel c.17G>A, p.R6H 2.138.761 Exon 0.4 0 0 0
Novel c.137 G>A, p.R46Q 2.138.641 Exon 0.4 0 0 0
rs3842752 c.*9C>T 2.137.649 3’UTR 20 7 27 21
rs3842753 c.*22C>A 2.137.636 3’UTR 26 10 34 28
SNP locations (-strand) are displayed counting from the first translated nucleotide in pre-proinsulin (INS). Base-pair positions are displayed counting from the
p-arm telomere of chromosome 11 (according to the Base position feature in the Human (Homo sapiens) Genome Browser Gateway Human Mar. 2006 [hg18]
assembly (http://genome.ucsc.edu/cgi-bin/hgGateway, assessed 19 June 2009). Minor allele frequencies (MAF) are given as a percentage.
A) Subsequent genotyping of 198 population-based individuals revealed a MAF of 0.7%
Control individuals were collected as a subset of the population based study Inter99 of middle-aged Danish individuals.
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(rhesus monkey, elephant, mouse, dog and horse) and
xenopus but is not conserved in lizard (S), platus (G) or
stikleback (Q). A mutation in the same codon, R6C, was
recently described in an English MODY family affecting
the proband, the mother and the maternal grandmother
[3], underlining a putative importance of this residue for
proper function of the signal peptide.
In a Czech MODY proband a previously described
R46Q mutation was found (Figure 1B). The mutation is
located at residue 22 of the B chain. The mutation co-
segregates with diabetes in two affected relatives and is
not present in any of the non-diabetic family members
or 96 controls. The proband, a 17-year old girl, was
diagnosed with diabetes at 13 years of age and had been
treated with insulin since onset of disease. Her mother
was diagnosed at 14 years of age with polyuria and poly-
dipsia, and had been treated with insulin since onset of
diabetes. The grandmother was diagnosed with diabetes
at 35 years of age and treated with OHA and insulin.
No coding mutations were found in GDM women or
GAD-negative type 1 diabetic patients.
It is very likely that the R46Q and R6H mutations are
disease causing and not just rare neutral polymorphisms.
In already published studies [1,3,7,8] a total of 1560
individuals primarily of Northern European ancestry
have been screened for INS mutations. The R46Q muta-
tion was identified in one Norwegian MODY family [7].
The mutation segregated with diabetes in the family.
The R6H mutation has not been identified in the 1560
examined individuals indicating that this mutation is not
a rare polymorphism. Furthermore, we have screened
additional 74 Danish individuals (data not shown) with-
out identifying the R46Q and R6H mutations.
Conclusion
Mutations in INS can be a rare cause of MODY and we
conclude that screening for mutations in INS should be
recommended in MODYX patients.
Abbreviations
GAD: Glutamic acid decarboxylase; GDM: Gestational diabetes mellitus; INS:
Insulin gene; MODY: Maturity-onset diabetes of the young; PNDM:
Permanent neonatal diabetes mellitus.
Acknowledgements
The study was supported by the Danish Medical Research Council and the
Danish Diabetes Association. The authors wish to thank A. Forman, I.-L.
Wantzin and M. Stendal for technical assistance, G. Lademann for secretarial
support, A. L. Nielsen for database management, M.M.H. Kristensen for grant
management, and the members of the Inter99 team. The authors from the
Czech Republic were supported by a grant “Monogenic diabetes in
Figure 1 Segregation of INS R6H (Figure 1A) and R46Q (Figure 1B) mutations in two MODY families. Symbols denote the following:
square, male; circle, female; empty symbol, normal glucose tolerant subject; filled symbol, diabetic person; quarter filled, impaired glucose
tolerance status/gestational diabetes; symbol with arrowhead, proband. The text, under each individual represents the following: Subject id; age
at examination (age at diagnosis); BMI (kg/m
2); NGT, normal glucose tolerance; IGT, impaired glucose tolerance; GDM, gestational diabetes
mellitus; DM, diabetes mellitus; treatment and mutation status; AAO, age of onset.
Boesgaard et al. BMC Medical Genetics 2010, 11:42
http://www.biomedcentral.com/1471-2350/11/42
Page 3 of 4childhood: from genetic to therapy” from Norway though the Norwegian
Financial Mechanism (No CZ0100).
Author details
1Steno Diabetes Centre and Hagedorn Research Institute, Gentofte, Denmark.
2Department of Pediatrics, Second Faculty of Medicine, Charles University,
Prague, Czech Republic.
3Center for Pregnant Women with Diabetes,
Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet,
Denmark.
4Faculty of Health Science, University of Copenhagen,
Copenhagen, Denmark.
5Research Centre for Prevention and Health,
Glostrup University Hospital, Glostrup, Denmark.
6Endocrinology and
Diabetes Unit, Department of Paediatric Medicine, Bambino Gesù Children’s
Hospital IRCCS, Piazza S. Onofrio 4, Rome, Italy.
7Institute of Biomedical
Science, Faculty of Health Sciences, University of Copenhagen, Copenhagen,
Denmark.
8Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark.
9Faculty of Health Sciences, University of Southern Denmark, Denmark.
Authors’ contributions
The concept and idea regarding the study belong to EAA, TWEB, OP and
TH. The collection of study subjects was planned and performed by SP, OC,
BO, JL, JL, PD, RB, FP, CP, TWEB, OP and TH.
The original hypothesis regarding the genetic study was conceived by EAA
and TWEB, and approved by OP and TH. Detail planning of analyses and
study design was performed by EAA and TWEB, and approved by FB, OP
and TH. EAA, TWEB, OP and TH contributed to the establishment of study
population databases specific for this study. Statistical analyses were
performed by EA and TWEB. The first manuscript was written by TWEB and
EAA (equal contributions) and the final draft was produced by TWEB, OP
and TH. All authors revised the manuscript and contributed to the
discussion.
Competing interests
T.W Boesgaard, E.A Andersson, R Bergholdt, F Pociot, O Pedersen and T
Hansen hold stock in Novo Nordisk, and O Pedersen and T Hansen have
received lecture fees from pharmaceutical companies. All other authors
declare that there is no competing interest associated with this manuscript.
Received: 13 August 2009 Accepted: 12 March 2010
Published: 12 March 2010
References
1. Bonfanti R, Colombo C, Nocerino V, et al: Insulin gene mutations as cause
of diabetes in children negative for five type 1 diabetes autoantibodies.
Diabetes care 2009, 32:123-125.
2. Colombo C, Porzio O, Liu M, et al: Seven mutations in the human insulin
gene linked to permanent neonatal/infancy-onset diabetes mellitus. J
Clin Invest 2008, 118:2148-2156.
3. Edghill EL, Flanagan SE, Patch AM, et al: Insulin mutation screening in
1,044 patients with diabetes: mutations in the INS gene are a common
cause of neonatal diabetes but a rare cause of diabetes diagnosed in
childhood or adulthood. Diabetes 2008, 57:1034-1042.
4. Støy J, Edghill EL, Flanagan SE, et al: Insulin gene mutations as a cause of
permanent neonatal diabetes. Proceedings of the National Academy of
Sciences 2007, 104:15040-15044.
5. Murphy R, Ellard S, Hattersley AT: Clinical implications of a molecular
genetic classification of monogenic beta-cell diabetes. Nat Clin Pract
Endocrinol Metab 2008, 4:200-213.
6. McCarthy MI, Hattersley AT: Learning from molecular genetics: novel
insights arising from the definition of genes for monogenic and type 2
diabetes. Diabetes 2008, 57:2889-2898.
7. Molven A, Ringdal M, Nordbo AM, et al: Mutations in the Insulin Gene
Can Cause MODY and Autoantibody-Negative Type 1 Diabetes. Diabetes
2008, 57:1131-1135.
8. Rubio-Cabezas O, Edghill EL, Argente J, Hattersley AT: Testing for
monogenic diabetes among children and adolescents with antibody-
negative clinically defined Type 1 diabetes. Diabet Med 2009,
26:1070-1074.
9. Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glümer C, Pisinger C:
A randomized non-pharmacological intervention study for prevention of
ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev
Rehabil 2003, 10:377-386.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2350/11/42/prepub
doi:10.1186/1471-2350-11-42
Cite this article as: Boesgaard et al.: Further evidence that mutations in
INS can be a rare cause of Maturity-Onset Diabetes of the Young
(MODY). BMC Medical Genetics 2010 11:42.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Boesgaard et al. BMC Medical Genetics 2010, 11:42
http://www.biomedcentral.com/1471-2350/11/42
Page 4 of 4